9705898-6
IPOS

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C07K 1/14, 14/435, 14/65, C12N 15/12 — A1

(11) International Publication Number: WO 96/40736

(43) International Publication Date: 19 December 1996 (19.12.96)

(21) International Application Number: PCT/US96/08113

(22) International Filing Date: 30 May 1996 (30.05.96)

(30) Priority Data:
08/482,271 7 June 1995 (07.06.95) US

(71) Applicant: CELTRIX PHARMACEUTICALS, INC. [US/US]; 3055 Patrick Henry Drive, Santa Clara, CA 95054-1815 (US).

(72) Inventors: SOMMER, Andreas; 100 Cimarron Court, Danville, CA 94506 (US). OGAWA, Yasushi; 310 Farallon Avenue, Pacifica, CA 94044 (US). TAO, Peggy; 3468 Whitman Way, San Jose, CA 95132 (US).

(74) Agents: PARK, Freddie, K. et al.; Morrison & Foerster L.L.P., 755 Page Mill Road, Palo Alto, CA 94304-1018 (US).

(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
With international search report.

(54) Title: METHOD OF PRODUCING IGF-I AND IGFBP-3 WITH CORRECT FOLDING AND DISULFIDE BONDING

(57) Abstract

The present invention provides a novel method for refolding insulin-like growth factor I (IGF-I) and insulin-like growth factor binding protein 3 (IGFBP-3). The method involves mixing of IGF-I and IGFBP-3 together in a cofolding reaction. The inventive cofolding method results in substantially higher yields of correctly folded protein for both molecules and alters the kinetics of refolding. The method includes the production of correctly folded IGF-I, IGFBP-3, and/or IGF-I/IGFBP-3 complex.